Bayer Consumer Health in 2026: Market Position, Strategy, and What's Next

Germany — 21 March 2026

Bayer Consumer Health, a division of the German pharmaceutical giant, remains a formidable, if sometimes understated, force within the global dietary supplement landscape. Its extensive portfolio, anchored by established brands like One-A-Day and Berocca, leverages a pharmaceutical-grade approach to product development and marketing. This strategy positions Bayer as a critical benchmark for both established players and emerging brands in an increasingly scrutinised and competitive sector, dictating trends in scientific validation and consumer trust.

Company Snapshot

Headquarters: Leverkusen, Germany

Key Brands: One-A-Day, Berocca, Elevit, Bepanthen, Canesten

Markets: Over 100 countries

Strategic Position and Recent Moves

Bayer Consumer Health's strategy continues to pivot on scientific substantiation and market expansion, particularly within the VMS and digestive health categories. The company has launched initiatives focusing on personalised supplement solutions in select European markets. This move, while nascent, signals an intent to compete with agile, data-driven brands like Ritual and Care/of. Bayer has announced strategic partnerships with gut microbiome research institutes to explore novel probiotic and postbiotic applications, directly challenging competitors like Nestlé Health Science and Danone in the advanced gut health space. Product launches have been incremental, focusing on line extensions and formulation improvements for existing brands, such as variants targeting the over-65 demographic introduced in North America. Geographically, Bayer has intensified its focus on emerging Asian markets, particularly India and Indonesia, establishing new distribution hubs and local marketing teams, aiming to capture a larger share of these rapidly growing, yet fragmented, supplement markets.

What Manufacturers Can Learn

Bayer's consistent emphasis on clinically backed formulations and robust regulatory compliance sets a high bar for the entire industry. For contract manufacturers, this translates into a demand for certified facilities, stringent quality control, and demonstrable traceability across the supply chain. Ingredient suppliers should note Bayer's increasing investment in proprietary research and patented ingredients, suggesting a preference for unique, scientifically validated components over commoditised offerings. The industry is clearly shifting from 'me-too' products to evidence-based solutions. Manufacturers need to invest in R&D and quality assurance as core competencies, not just checkboxes. Furthermore, the entry into personalised nutrition highlights a growing market for flexible manufacturing capabilities that can support diverse SKU variations and smaller batch sizes, moving away from mass production of generic formulations. In our experience as a manufacturer, this trend towards smaller, more varied production runs requires significant operational flexibility whilst maintaining the same exacting quality standards that pharmaceutical-grade facilities demand.

Risks and Headwinds

Despite its strong market position, Bayer Consumer Health faces significant challenges. Regulatory divergence across its vast operational footprint, particularly concerning health claims and novel ingredients, poses an ongoing compliance burden. The company's pharmaceutical legacy, while an advantage in trust, can sometimes hinder agility in responding to rapidly evolving consumer trends compared to nimbler, digitally native brands. Competitively, the rise of direct-to-consumer (DTC) supplement companies, often leveraging aggressive digital marketing and subscription models, presents a persistent threat to Bayer's traditional retail-centric distribution. Financially, the broader Bayer Group's ongoing litigation surrounding Roundup continues to cast a shadow, potentially diverting capital and executive focus from the consumer health division. Bayer's sheer size is both its strength and its weakness. Adapting its pharmaceutical-grade infrastructure to the fast-paced, often less regulated, supplement market requires constant re-evaluation, especially in the face of intense competition from brands like GNC and Holland & Barrett in established markets, and local champions in emerging economies.

The B2B Verdict

Supplement businesses should absolutely be watching Bayer Consumer Health. Its strategic moves, particularly in scientific validation and personalised nutrition, offer a glimpse into the future of the industry. Partnering opportunities exist for ingredient suppliers with novel, evidence-backed compounds, and for contract manufacturers capable of high-spec, flexible production. Competing directly requires significant investment in R&D and a robust regulatory strategy, but Bayer's scale also leaves niches open for agile, specialised players.

This trend is being actively addressed by UK manufacturing partners including Supplement Factory.